Cecilia Li

Cecilia Li is a partner based in Ogier's Hong Kong office. She has a broad corporate finance practice with particular expertise in using BVI and Cayman companies in capital markets transactions, mergers and acquisitions, private equity investments, corporate reorganisations and joint ventures. She also has extensive experience in banking and syndicated loan transactions, mortgage backed securities transactions and debt restructurings.

Background and experience

Cecilia Li is a corporate partner in Ogier's Hong Kong office. She advises on a broad range of corporate and corporate finance transactional matters, including equity and debt offerings, initial public offerings on stock exchanges globally (including Mainland China, Hong Kong, Taiwan and the United States of America), mergers and acquisitions, take-private transactions, banking and syndicated loan transactions, mortgage backed securities transactions and complex corporate and debt restructuring. She is part of Ogier's multi-disciplinary Private Equity team and has extensive experience in advising downstream corporate transactions – acquisitions, investments and exits.

As a native Mandarin speaker (also fluent in English and Cantonese), Cecilia regularly advises both international and Chinese clients across a broad range of corporate, fundraising and financing transactions. She is highly valued for her combination of legal expertise and superior language proficiency. Cecilia's clients include major Chinese state-owned enterprises, listed and private companies, major investment banks, financial institutions and private equity houses.

Cecilia started her career with Norton Rose Fulbright in London and subsequently joined Linklaters' Hong Kong office's capital markets team for years.

Recent representative transactions:

Capital markets (equity and debt)

• Mirxes on its HK$880.5 million 18A IPO on HKEX (2629.HK)
• Guming on its HK$1.81 billion IPO on the HKEX (1364.HK)
• Yuexiu Property on its HK$8.36 billion rights issue transaction – outstanding transaction of 2023 by China Business Law Journal
• Cloud Factory on its HK$529 million IPO on HKEX(2512.HK)
• Xuan Wu Cloud on its HK$1.67 billion IPO on HKEX(2392.HK)
• China Conch Environment Protection on its listing by introduction on HKEX (0587.HK)
• Hangzhou Tigermed on its HK$10.7 billion H shares listing on HKEX (3347.HK)
• Wintergreen Acquisition on its US$50 million initial public offering on NASDAQ
• Future Vision II in connection with its US$57.5 million listing on NASDAQ
• WORK Medical on its US$8 million IPO on NASDAQ (WOK)
• Jiangsu Yahong Meditech on its CNY2.528 billion IPO on the Shanghai Science and Technology Innovation Board (688176.SS)
• Huali Group on its CNY360 million IPO on the Shenzhen Growth Enterprise Market (300979.CH)
• Baofeng Energy on its CNY815 million IPO on the Shanghai Stock Exchange (600989.SH)
• China Communications Construction on its issuance of CNY7.1 billion offshore green bonds
• Yuexiu Real Estate Investment Trust on its issuance of CNY1 billion notes (0405.HK)
• China Mengniu Dairy on its HKD4.86 billion structuring of an employee incentive scheme and issuance of convertible bonds
• China South City, Sino-Ocean Group, Zensun Enterprises, China Fortune Land Development, Yincheng International, Sansheng Holdings and Sichuan Transportation Investment Group on their liability management transactions, including consent solicitation and exchange offer

M&A / Private Equity

• Ronshine Service on its HK$300 million privatisation and delisting from HKEX (2207.HK)
• Ping An to sell 42% stake in Autohome to Haier Group for US$1.8 billion
• Silver Group's acquisition of Brazilian mining company for US$D420 million
• Vantone Neo Development Group on its proposed US$324 million acquisition of Source Photonics
• JD Property in connection with its acquisition of LiFung Centre from M&A Real Estate in London
• China Three Gorges for its acquisition of Jordan and Egypt based photovoltaic power station
• Newater Technology's privatisation from NASDAQ
• Ossen Innovation's privatisation from NASDAQ
• Series financings for Mirxes, Suzhou Cure Genetics, Byton, Sumscope

Admitted in:
2024 – British Virgin Islands
2013 – England and Wales 

Cecilia is a Registered Foreign Lawyer regulated by the Law Society of Hong Kong.

Education:

• LLB, University of Warwick
• MSc in Sociology, University of Oxford
• LPC, BPP University